Top Contract Research Organizations (CROs) in Canada
Nominate a Company
Usually, the qualified subscribers of our magazine nominate companies with whom they have collaborated and experienced exceptional results to be in this list. Did a company you recently worked with give you stellar results and ROI? Did it turn out to be one you would wholeheartedly recommend to peers? Or do you know of such an outstanding company through your network? Please fill in the details below and nominate them to be featured here.
Top Contract Research Organizations (CROs) in Canada
CRO News
Advancing Antibacterial Treatment Strategies for Better Infection Control in Canada
Wednesday, August 19, 2026
Fremont, CA: Antibacterial treatments are designed to eliminate harmful bacteria, reduce the risk of infection spread, and support the body's natural healing processes. Advances in medical science across Canada have enabled healthcare professionals to diagnose bacterial infections with greater accuracy and deliver targeted treatments through topical applications, oral medications, intravenous therapies, and preventive care strategies. How Do Antibacterial Treatments Help Control Bacterial Infections? Antibacterial treatments are designed to kill bacteria and disrupt their growth, reproduction or survival. Treatment depends on the n
Advanced Therapies Put New Pressure on Canadian CDMO Selection
Friday, August 14, 2026
A pharmaceutical company developing an advanced therapy may reach a difficult decision before manufacturing begins. The scientific platform can be promising, yet the available CDMO options may not have the facilities, technical experience or development processes needed to move the program forward. For sponsors working with complex modalities, choosing a manufacturing partner has become part of the development strategy rather than a later procurement decision. The issue is especially relevant when a therapy requires production methods that differ from conventional small-molecule manufacturing. A CDMO may have broad pharmaceutical experience but still lack the specific technical
Technology Adoption Becomes a Practical Test for Pharmaceutical CDMOs
Friday, August 14, 2026
Technology adoption in pharmaceutical manufacturing is increasingly being judged by the problems it solves for clients. For companies developing advanced therapies, a new platform or production method has limited value if the CDMO cannot apply it reliably within the development process. The technology question has therefore moved closer to the center of outsourcing decisions. A sponsor evaluating a CDMO may ask how the partner uses technology to support a complex program. The answer can reveal more than a list of equipment or technical capabilities. It can show whether the CDMO has built its processes around the requirements of newer therapies or is trying to fit those programs
Outsourcing Decisions for Complex Modalities Begin Earlier in Development
Friday, August 14, 2026
For sponsors working with complex modalities, the decision to outsource manufacturing may come well before a product is ready for commercial production. The choice of CDMO can influence how the development program takes shape, especially when the sponsor does not have the facilities or technical resources to handle specialized manufacturing work internally. Timing can make the decision difficult. Choosing a partner too early may mean the sponsor does not yet have a clear picture of what the program will eventually require. Waiting too long, however, can narrow the options if the therapy later needs a CDMO with specialized facilities or technical expertise. Many sponsor
